Skip to Main Content (Press Enter)

Logo UNIBS
  • ×
  • Home
  • Persone
  • Strutture
  • Competenze
  • Pubblicazioni
  • Professioni
  • Corsi
  • Insegnamenti
  • Terza Missione
  • Attrezzature

Competenze & Professionalità
Logo UNIBS

|

Competenze & Professionalità

unibs.it
  • ×
  • Home
  • Persone
  • Strutture
  • Competenze
  • Pubblicazioni
  • Professioni
  • Corsi
  • Insegnamenti
  • Terza Missione
  • Attrezzature
  1. Pubblicazioni

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report

Articolo
Data di Pubblicazione:
2026
Abstract:
Background Brain metastases (BM) occur in up to 50% of patients with HER2-positive metastatic breast cancer (MBC) and represent a major clinical challenge due to limited CNS drug penetration. In recent years, novel anti-HER2 agents-such as trastuzumab deruxtecan (T-DXd) and tucatinib-have shown promising intracranial efficacy and are now recommended after progression on first-line therapies. However, no prospective data are available to guide optimal treatment sequencing, particularly in the CNS setting.Case presentation We report the case of a 37-year-old woman with HER2-positive, hormone receptor-negative MBC and symptomatic BM who progressed after treatment with T-DXd and a tucatinib-based regimen. Remarkably, fourth-line therapy with Trastuzumab Emtansine (T-DM1) resulted in a durable intracranial response, maintained over 24 months, with good clinical tolerance and manageable side effects.Results this case underscores the potential of T-DM1 to remain an effective treatment option even after the failure of next-generation HER2-targeted therapies. The sustained response may be attributed to tumor biology, prior radiotherapy-induced modulation of the blood-brain barrier, or enhanced drug delivery to CNS lesions. Given its favorable toxicity profile and ease of administration, T-DM1 retains clinical relevance in selected patients.Conclusion T-DM1 may offer meaningful benefit in HER2+ MBC with BM, especially where newer agents fail or are contraindicated. Further studies are needed to clarify optimal sequencing strategies.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
HER-2; Treatment strategy; brain metastasis; breast cancer; case report
Elenco autori:
Trevisan, Benedetta; Cosentini, Deborah; Schivardi, Greta; Piazza, Francesca; Scartabellati, Giulia; Moretti, Laura; Vassalli, Lucia; Ippolito, Giuseppe; Donato, Francesco; Berruti, Alfredo; Laganà, Marta; Pedersini, Rebecca
Autori di Ateneo:
BERRUTI ALFREDO
Cosentini Deborah
LAGANÀ MARTA
Link alla scheda completa:
https://iris.unibs.it/handle/11379/651328
Link al Full Text:
https://iris.unibs.it/retrieve/handle/11379/651328/396499/fonc-16-1865921.pdf
Pubblicato in:
FRONTIERS IN ONCOLOGY
Journal
  • Assistenza
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Designed by Cineca | 26.11.1.0